Generic Name: lenacapavir
Drug Class: Capsid Inhibitors
Company: Gilead Sciences
Approval Status: Approved
Generic Version Available: No
Experimental Code: GS-6207
Sunlenca (lenacapavir) is a long-acting injectable HIV medication. It is approved for treatment experienced people with multidrug-resistant virus who are currently on a failing regimen. It must be used in combination with other antiretrovirals.
Senlenca is not yet included in the U.S. Department of Health and Human Services Antiretroviral Guidelines for Adults and Adolescents.
Visit https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/0 for the full DHHS guidelines.
Sunlenca is a long-acting injectable HIV medication. Approved in December 2022, it is the first HIV capsid inhibitor.
Sunlenca is approved for heavily treatment-experienced adults with multidrug-resistant HIV whose are unable to achieve and maintain viral suppression due to resistance, intolerance or safety considerations. Sunlenca is not a complete regimen, and it must be combined with other antiretrovirals.
Sunlenca is a long-acting injectable HIV medication taken every six months. People who wish to use Sunlenca have two initiation options:
Two Sunlenca tablets on Day 1 and Day 2 plus two subcutaneous injections on Day 1.
Two Sunlenca tablets on Day 1 and Day 2, one tablet on Day 8 and two subcutaneous injections on Day 15.
After initiation, Sunlenca is given by injection every six months.
The most common side effects of Sunlenca are nausea and injection site reactions, such as pain, redness or swelling.
For a review of drug interactions, including prescription and over-the-counter medications and supplements that should not be taken with Sunlenca or may require dose adjustments, consult the Sunlenca package insert.
For More Info: https://www.sunlenca.com/
Last Reviewed: December 23, 2022